Hereditary – Talk Bio

Atsena reels in $150M to advance work on ocular gene therapies

3 weeks ago talkbio0Tagged Atsena, ATSN-101, ATSN-201, Blindness, Cloning Vectors, Dependovirus, Hereditary, Retinal Diseases, Retinoschisis, Juvenile, X-Linked, United States Food and Drug Administration

Atsena, Retinoschisis, Juvenile, X-Linked, United States Food and Drug Administration, Dependovirus, Cloning Vectors, Hereditary, Retinal Diseases, Blindness, ATSN-201, ATSN-101

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

3 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy

Ocuphire Pharma Acquires Opus Genetics, Expanding into Inherited Retinal Disease Gene Therapies

6 months ago talkbio0Tagged Acquisition, Biological Factors, gene therapy, Hereditary, IRDs, Ocuphire Pharma, ophthalmic treatments, Opus, Retinal Diseases, Science of genetics

Ocuphire Pharma, Opus Genetics, gene therapy, inherited retinal diseases (IRDs), merger, acquisition, biopharmaceutical, ophthalmic treatments